WO2023007312 - PROGESTOGEN-ONLY ORAL CONTRACEPTION
National phase entry:
Publication Number
WO/2023/007312
Publication Date
02.02.2023
International Application No.
PCT/IB2022/056637
International Filing Date
19.07.2022
Title **
[English]
PROGESTOGEN-ONLY ORAL CONTRACEPTION
[French]
CONTRACEPTION ORALE À BASE DE PROGESTATIF SEUL
Applicants **
NAVAD LIFE SCIENCES PTE
36 Robinson Road
#13-01
City House 068877, SG
Inventors
OETTEL, Michael
Beethovenstrasse 30
07743 Jena, DE
OSTERWALD, Hermann
Annette Kolb Weg 9
79410 Badenweiler, DE
KOCHHAR, Prithi
142 Sunder Nagar
New Delhi 110003, IN
Priority Data
17/385,057
26.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1129 | |
| EPO | Filing, Examination | 6761 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 11769 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to a method for providing progestogen only contraception. The method consists of orally administering to a human subject desiring contraception a tablet consisting of about 0.115 mg to about 0.145 mg of levonorgestrel (LNG) and one or more pharmaceutical acceptable excipients for a treatment period of at least twenty-eight days.[French]
La présente invention se rapporte à une méthode de contraception à base de progestatif seul. La méthode consiste à administrer par voie orale à un sujet humain souhaitant une contraception, un comprimé constitué d'environ 0,115 mg à environ 0,145 mg de lévonorgestrel (GNL) et d'un ou de plusieurs excipients pharmaceutiquement acceptables pendant une période de traitement d'au moins vingt-huit jours.